An innovative device and app using smartphone technology and improved componentry to provide real-time, at-home asthma management and save lives

Bedfont is a UK-based medical device SME established in 1976\. The project is led by an extensive, multidiscipline team with a combined experience in breath analysis of over 50 years.

Poor asthma management contributes to 250K preventable deaths globally each year -- around 60% of asthma deaths. It also leads to $100B in healthcare and economic costs, 136M hospital bed days and 23M missed school days, burdening healthcare systems and industries. In the UK, approximately 5.4M people have asthma, with only 30% of adults and 53% of children achieving well-controlled conditions.

To this end, Bedfont is developing NObreatHome, a low-cost, easy-to-use Fractional Exhaled Nitric Oxide (FeNO) device and app for real-time, at-home asthma monitoring. By innovatively using smartphone technology and eliminating the need for costly components, NObreatHome will make at-home FeNO testing and real-time airway inflammation monitoring available for an initial investment of under £300\. This could reduce hospital admissions by 30%, potentially saving £69M in the UK.

Furthermore, this solution will particularly benefit lower socioeconomic groups, ethnic minorities and those who live in urban areas, where air pollution is higher and access to healthcare and consistent asthma management is often limited.